Investor.ariad.com

The Japanese pharmaceutical company Takeda is buying Cambridge, Massachussets-based Ariad Pharmaceuticals for $24 a share. The deal is valued at about $5.2 billion and expected to close in February. "This is a very exciting time for Takeda as we will...

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.; ed al. The Lancet Onc. 2016, DOI: 10.1016/S...

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced on January 22, 2024 the appointment of Thomas J. DesRosier, Esq. (’80) to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible...

To be read and ingested with a grain of salt… Yes – there are some good points in this offering, HOWEVER – the first sentence alone discusses ‘cancer treatment’ – NOT cancer cure. “Moonshot”? Is it 1972 all over again with another ‘War on Cancer?’ YOU...

Is It Possible to Control Cancer Without Killing It? | Jerome Groopman: Jerome Groopman on an experimental cancer drug that can transform malignant cells into healthier ones. An experimental new drug can make some leukemic cells mature into healthier...